These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33940028)

  • 1. Effects of Secondary Package on Freeze-Dried Biopharmaceutical Formulation Stability During Dropping.
    Fang WJ; Liu JW; Barnard J; Wang H; Qian YC; Xu J
    J Pharm Sci; 2021 Aug; 110(8):2916-2924. PubMed ID: 33940028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Sub-Visible Particle and Free Radical formation of a Freeze-Dried Monoclonal Antibody Formulation During Dropping.
    Fang WJ; Liu JW; Zheng HJ; Shen BB; Wang X; Kong Y; Jing ZY; Gao JQ
    J Pharm Sci; 2021 Apr; 110(4):1625-1634. PubMed ID: 33049261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary Packages cannot Protect Liquid Biopharmaceutical Formulations from Dropping-Induced Degradation.
    Fang WJ; Liu JW; Gao H; Qian YC; Gao JQ; Wang H
    Pharm Res; 2021 Aug; 38(8):1397-1404. PubMed ID: 34282500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Freeze-Dried Biopharmaceutical Formulations are Surprisingly Less Stable than Liquid Formulations during Dropping.
    Fang WJ; Pang MJ; Liu JW; Wang X; Wang H; Sun MF
    Pharm Res; 2022 Apr; 39(4):795-803. PubMed ID: 35314998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Grinding-Induced Subvisible Particles and Free Radicals in a Freeze-Dried Monoclonal Antibody Formulation.
    Jing ZY; Huo GL; Sun MF; Shen BB; Fang WJ
    Pharm Res; 2022 Feb; 39(2):399-410. PubMed ID: 35083639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of protein sub-visible particles during powder grinding of a monoclonal antibody.
    Qian C; Wang G; Wang X; Barnard J; Gao JQ; Bao W; Wang H; Li F; Ingle RG; Fang WJ
    Eur J Pharm Biopharm; 2020 Apr; 149():1-11. PubMed ID: 32006605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking.
    Jin MJ; Ge XZ; Huang Q; Liu JW; Ingle RG; Gao D; Fang WJ
    Pharm Res; 2024 Feb; 41(2):321-334. PubMed ID: 38291165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Freeze-Dried Monoclonal Antibody Formulations are Unexpectedly More Prone to Degradation Than Liquid Formulations Under Shaking Stress.
    Fang WJ; Ingle RG; Liu JW; Ge XZ; Wang H
    J Pharm Sci; 2022 Jul; 111(7):2134-2138. PubMed ID: 35257695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
    Santana H; García G; Vega M; Beldarraín A; Páez R
    PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Annealing on Visible-Bubble Formation and Stability Profiles of Freeze-Dried High Concentration Omalizumab Formulations.
    Gao H; Ge XZ; Liu JW; Wang ST; Xu J; Fang WJ
    Mol Pharm; 2024 Apr; 21(4):1691-1704. PubMed ID: 38430187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of protein sub-visible particles during vacuum degassing of etanercept solutions.
    Wang H; Zheng HJ; Wang Z; Bai H; Carpenter JF; Chen S; Fang WJ
    Int J Biol Macromol; 2014 May; 66():151-7. PubMed ID: 24513220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations.
    Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
    Eur J Pharm Biopharm; 2020 Feb; 147():45-56. PubMed ID: 31866444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
    Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive conditions during primary drying as a contemporary approach to optimise freeze-drying cycles of biopharmaceuticals.
    Bjelošević M; Seljak KB; Trstenjak U; Logar M; Brus B; Ahlin Grabnar P
    Eur J Pharm Sci; 2018 Sep; 122():292-302. PubMed ID: 30006178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved water dispersibility and photostability in folic acid nanoparticles with transglycosylated naringin using combined processes of wet-milling and freeze-drying.
    Semba K; Kadota K; Arima H; Nakanishi A; Tandia M; Uchiyama H; Sugiyama K; Tozuka Y
    Food Res Int; 2019 Jul; 121():108-116. PubMed ID: 31108730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.
    Abdul-Fattah AM; Truong-Le V; Yee L; Nguyen L; Kalonia DS; Cicerone MT; Pikal MJ
    J Pharm Sci; 2007 Aug; 96(8):1983-2008. PubMed ID: 17286290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The formation and effect of mannitol hemihydrate on the stability of monoclonal antibody in the lyophilized state.
    Anko M; Bjelošević M; Planinšek O; Trstenjak U; Logar M; Ahlin Grabnar P; Brus B
    Int J Pharm; 2019 Jun; 564():106-116. PubMed ID: 30999044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.